NeuroScientific Biopharmaceuticals Balance Sheet Health

Financial Health criteria checks 6/6

NeuroScientific Biopharmaceuticals has a total shareholder equity of A$5.4M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$5.4M and A$85.7K respectively. NeuroScientific Biopharmaceuticals's EBIT is A$155.3K making its interest coverage ratio -0.9. It has cash and short-term investments of A$5.0M.

Key information

Debt to equity ratio

AU$0

Debt

Interest coverage ratio	-0.9x
Cash	AU$4.95m
Equity	AU$5.35m
Total liabilities	AU$85.68k
Total assets	AU$5.44m

Recent financial health updates

Is NeuroScientific Biopharmaceuticals (ASX:NSB) In A Good Position To Deliver On Growth Plans?

May 25

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth

Jan 27

NeuroScientific Biopharmaceuticals (ASX:NSB) Is In A Good Position To Deliver On Growth Plans

Oct 07

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Can Afford To Invest In Growth

Jun 23

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth

Mar 10

We're Hopeful That NeuroScientific Biopharmaceuticals (ASX:NSB) Will Use Its Cash Wisely

Nov 18

Recent updates

Is NeuroScientific Biopharmaceuticals (ASX:NSB) In A Good Position To Deliver On Growth Plans?

May 25

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth

Jan 27

NeuroScientific Biopharmaceuticals (ASX:NSB) Is In A Good Position To Deliver On Growth Plans

Oct 07

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Can Afford To Invest In Growth

Jun 23

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth

Mar 10

We're Hopeful That NeuroScientific Biopharmaceuticals (ASX:NSB) Will Use Its Cash Wisely

Nov 18

Financial Position Analysis

Short Term Liabilities: NSB's short term assets (A$5.0M) exceed its short term liabilities (A$85.7K).

Long Term Liabilities: NSB has no long term liabilities.

Debt to Equity History and Analysis

Debt Level: NSB is debt free.

Reducing Debt: NSB had no debt 5 years ago.

Debt Coverage: NSB has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: NSB has no debt, therefore coverage of interest payments is not a concern.

NeuroScientific Biopharmaceuticals Balance Sheet Health

Financial Health criteria checks 6/6

Key information

Recent financial health updates

Is NeuroScientific Biopharmaceuticals (ASX:NSB) In A Good Position To Deliver On Growth Plans?

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth

NeuroScientific Biopharmaceuticals (ASX:NSB) Is In A Good Position To Deliver On Growth Plans

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Can Afford To Invest In Growth

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth

We're Hopeful That NeuroScientific Biopharmaceuticals (ASX:NSB) Will Use Its Cash Wisely

Recent updates

NeuroScientific Biopharmaceuticals Limited, Annual General Meeting, Nov 06, 2024

NeuroScientific Biopharmaceuticals Limited Announces Changes to Board of Directors

NeuroScientific Biopharmaceuticals Limited Announces Resignation of Stephen Carter as CEO Effective 31 December 2023

Linda Friedland Steps Down from the Board of NeuroScientific Biopharmaceuticals Limited, Effective 17 November 2023

Neuroscientific Biopharmaceuticals Limited Announces Board Changes

NeuroScientific Biopharmaceuticals Ltd Appoints Linda Friedland as Independent Non-Executive Director

NeuroScientific Biopharmaceuticals Limited, Annual General Meeting, Nov 23, 2023

Neuroscientific Biopharmaceuticals Limited Announces Chief Executive Officer Changes

NeuroScientific Biopharmaceuticals Files A New Patent, Entitled "Neuroprotective Compositions and Methods"

NeuroScientific Biopharmaceuticals Limited Announces Appointment of Mr. Paul Rennie as Interim CEO

Less than half of directors are independent

NeuroScientific Biopharmaceuticals Limited Announces Management Changes

NeuroScientific Biopharmaceuticals Limited, Annual General Meeting, Nov 24, 2022

NeuroScientific Biopharmaceuticals Ltd Announces Resignation of Matt Liddelow as Managing Director

Neuroscientific Biopharmaceuticals Ltd. Announces HREC Decision to Not Approve Phase I Clinical Trial

NeuroScientific Biopharmaceuticals Limited Announces Human Research Ethics Committee Submission for Phase I Clinical Trial

NeuroScientific Biopharmaceuticals Limited Announces Recruitment of First Subject Recruited for Early-Phase Clinical Trial

NeuroScientific Biopharmaceuticals Limited Announces Clarification of Results in Ms Animal Study

NeuroScientific Biopharmaceuticals Limited Announces Positive Preliminary Results of Lead Drug Candidate EMTINB

Neuroscientific Biopharmaceuticals Ltd Receives Approval from the Human Research Ethics Committee for its Early-Phase Clinical Trial of Lead Drug Candidate EmtinBTM

Is NeuroScientific Biopharmaceuticals (ASX:NSB) In A Good Position To Deliver On Growth Plans?

Neuroscientific Biopharmaceuticals Limited Announces Submission for HREC Approval of Early-Phase Clinical Trial of EmtinBTM

Less than half of directors are independent

NeuroScientific Biopharmaceuticals Limited Announces Positive Safety Result Supports Advance to Clinical Trials

NeuroScientific Biopharmaceuticals Limited Announces Management Appointments

NeuroScientific Biopharmaceuticals Limited Successful Completion of Key Studies in Lead Up to Phase I Clinical Studies

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth

Neuroscientific Biopharmaceuticals Limited Announces Positive Off-Target Safety Assessment of Emtinb

Neuroscientific Biopharmaceuticals Limited Announces Positive Results in Biomarker Characterisation of Emtins

NeuroScientific Biopharmaceuticals (ASX:NSB) Is In A Good Position To Deliver On Growth Plans

Non-Executive Chairman recently bought AU$100k worth of stock

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Can Afford To Invest In Growth

Non-Executive Chairman Brian Leedman has left the company

Companies Like NeuroScientific Biopharmaceuticals (ASX:NSB) Are In A Position To Invest In Growth

New 90-day low: AU$0.21

Non-Executive Chairman exercised options to buy AU$69k worth of stock.

New 90-day low: AU$0.23

New 90-day low: AU$0.24

Neuroscientific Biopharmaceuticals Limited Initiates A New Preclinical Program in Partnership with the Institute of Respiratory Health and the University of Western Australia

We're Hopeful That NeuroScientific Biopharmaceuticals (ASX:NSB) Will Use Its Cash Wisely

New 90-day high: AU$0.35

New 90-day high: AU$0.32

New 90-day high: AU$0.27

New 90-day high - AU$0.24

New 90-day high - AU$0.24

Financial Position Analysis

Debt to Equity History and Analysis

Balance Sheet

Discover healthy companies